ArchiMed reaps 4x on Bomi sale to UPS

The deal gives UPS temperature-controlled facilities in 14 countries and adds 3,000 employees to the buyer's network in Europe and Latin America, it said in a statement. The acquisition will play a key role in the delivery of pharmaceutical and biologic treatments that increasingly require time-critical and temperature-sensitive logistics.

ArchiMed took private Bomi in May 2019 via its maiden mid-market fund, MED Platform I, for EUR 70m, and has made at least three bolt-ons including Logifarma, Florence Shipping, and Deco Pharma. 

The vendor made a 4x return on the sale, according to a source familiar with the situation, who added that the deal was worth "several hundred million dollars".

The vendor circulated teasers for the company in March, in a Morgan Stanley-led process, as reported.

Bomi was marketed off EUR 40m EBITDA in 2022 and generated EUR 27m in 2020. The company had around EUR 300m sales in 2022, according to a statement. 

ArchiMed said in a statement that MP I’s total performance stands at 2.2x invested capital or an annualised return of 69%. The fund was 70% deployed as of April 2021, according to Unquote Data.

The GP launched its second mid-cap fund at the beginning of the year, as reported. 

The transaction is expected to close by the end of the year. 

Company
Italy-based Bomi Group is a company in the field of integrated logistics serving more than 150 healthcare customers worldwide, including in the medical device, in vitro diagnostics, biomedical, and pharmaceutical sectors. 

The group is present in 14 countries and has its own fleet of vehicles for daily deliveries to hospitals, clinics, laboratories, pharmacies, and home patients.

Advisors 
ArchiMed – Morgan Stanley (M&A); Latham & Watkins (legal). 
UPS – JP Morgan (M&A).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Exits
• Industrials
• Healthcare
• Archimed